NOVARTIS AG |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 96.01 CHF | +2.15% |
|
+2.64% | +13.13% |
| 06-24 | Foreign banks target Switzerland after UBS takeover of Credit Suisse | RE |
| 06-24 | NOVARTIS AG : Barclays reaffirms its Sell rating | ZD |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
Novartis AG is one of the world's leaders in the design, manufacturing, and marketing of pharmaceutical products. Net sales (excluding discontinued operations) break down by therapeutic area as follows:
- oncology (29.9%);
- immunology (17.2%);
- cardiovascular, renal and metabolic diseases (14.1%);
- neuroscience (8.9%).
The remaining net sales (29.9%) are from contract manufacturing of pharmaceutical products.
At the end of 2023, Novartis AG had 33 production sites worldwide.
Net sales are distributed geographically as follows: Europe (33%), the United States (39.5%), Asia/Africa/Australasia (20.5%), Canada and Latin America (7%).
Sector
Pharmaceuticals
Calendar
18/07/2024
- Q2 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
22
Last Close Price
107.5
USD
Average target price
110.3
USD
Spread / Average Target
+2.66%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +13.13% | 219B | |
| +52.70% | 801B | |
| +41.58% | 631B | |
| -4.86% | 359B | |
| +21.96% | 337B | |
| +11.47% | 305B | |
| +17.72% | 245B | |
| +4.46% | 231B | |
| +10.46% | 171B | |
| -1.49% | 161B |
- Stock Market
- Equities
- NOVN Stock
- News Novartis AG
- Berenberg Raises Price Target on Novartis to CHF77 From CHF74, Maintains Hold Rating
